Login / Signup
Therapeutic indications for antibody-drug conjugates estimated from HER2 and p53 expressions in endometrial carcinoma.
Junya Nakajima
Mitsutake Yano
Sumika Zaitsu
Kouichi Kamada
Akira Yabuno
Kosei Hasegawa
Eiji Kobayashi
Masanori Yasuda
Published in:
Human pathology (2024)
This study presents detailed clinicopathological characteristics and the prognostic impact of HER2-positivity in endometrial carcinomas. HER2-targeted antibody-drug conjugate therapy may be broadly applicable to endometrial carcinoma.
Keyphrases
</>
endometrial cancer
cancer therapy
high grade
drug delivery
stem cells